Potent inhibitor of platelet aggregation
Related Products
Labeled Version(s)
900028113,14-dihydro Prostaglandin E1-d4
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

13,14-dihydro Prostaglandin E1

Item No. 13610

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
9-oxo-11α,15S-dihydroxy-prostan-1-oic acid
CAS Number
19313-28-1
Synonyms
  • PGE0
  • 13,14-dihydro PGE1
Molecular Formula
C20H36O5
Formula Weight
356.5
Purity
≥98%
Formulation (Request formulation change)
A 5 mg/ml solution in methyl acetate
Solubility(Learn about Variance in Solubility)
DMF: >100 mg/mlDMSO: >50 mg/mlEthanol: >50 mg/mlPBS (pH 7.2): >1.6 mg/ml
SMILES
O=C1[C@H](CCCCCCC(OC)=O)[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C1
InChi Code
InChI=1S/C21H38O5/c1-3-4-7-10-16(22)13-14-18-17(19(23)15-20(18)24)11-8-5-6-9-12-21(25)26-2/h16-18,20,22,24H,3-15H2,1-2H3/t16-,17+,18+,20+/m0/s1
InChi Key
WWCDWHSPGWIYEH-JRBPQWBISA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $52

    Add

    1 mg

    $96

    Add

    5 mg

    $396

    Add

    10 mg

    $692

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    13,14-dihydro Prostaglandin E1 (13,14-dihydro PGE1) is a biologically active metabolite of PGE1 with comparable potency to the parent compound.1,2 It is an inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC50 values of 31 and 21 nM, respectively.3 13,14-dihydro PGE1 is a slightly more potent inhibitor of ADP-induced human platelet aggregation than PGE1 (Item No. 13010) which has an IC50 value of 40 nM.4 Also, 13,14-dihydro PGE1 was shown to activate adenylate cyclase in NCB-20 hybrid cells with a Kact value of 668 nM.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Änggård, E. The biological activities of three metabolites of prostaglandin E1. Acta Physiol. Scand. 66(4), 509-510 (1966).

    2. Hamberg, M., and Samuelsson, B. On the metabolism of prostaglandins E1 and E2 in man. The Journal of Biological Chemisty 246(22), 6713-6721 (1971).

    3. Kobzar, G., Mardla, V., Järving, I., et al. Comparison of the inhibitory effect of E-prostaglandins in human and rabbit platelet-rich plasma and washed platelets. Comp. Biochem. Physiol. 106(2), 489-494 (1993).

    4. Kobzar, G., Mardla, V., Järving, I., et al. Antiaggregating potency of E-type prostaglandins in human and rabbit platelets. Proc. Estonian Acad. Sci. Chem. 40(N3), 179-180 (1991).

    5. Blair, I.A., Hensby, C.N., and MacDermot, J. Prostacyclin-dependent activation of adenylate cyclase in a neuronal somatic cell hybrid: Prostanoid structure-activity relationships. Br. J. Pharmac. 69(3), 519-525 (1980).